Experimental Hematology & Oncology (2023) 12:74
Anzeige
After online publication of the article1, the authors noticed Table 1 and 2 should have been published in the main article were inadvertently submitted and processed as Supplementary files.
The correct tables are published with this erratum.
Table 1
Properties of bispecific antibodies for multiple myeloma
Author | NCT No. | Agents | Ig type | Structural format | Target | Phase | References |
|---|---|---|---|---|---|---|---|
Firestone R | N/A | Teclistamab | IgG4 | 1 + 1 symmetric | BCMA/CD3 | post-marketing revaluation | [4] |
Mohty M | NCT 04649359 | Elranatamab | IgG2a | 1 + 1 symmetric | BCMA/CD3 | II | [5] |
Lee HC | NCT03761108 | Linvoseltamab | IgG4κ | 1 + 1 symmetric | BCMA/CD3 | I/II | [6] |
Sun MY | NCT 04984434 | F182112 | -- | -- | BCMA/CD3 | I | [7] |
Morillo D | NCT 03399799 | Talquetamab | IgG4PAA | 1 + 1 symmetric | GPRC5D/CD3 | I | [8] |
Schinke CD | NCT 04634552 | Talquetamab | IgG4PAA | 1 + 1 symmetric | GPRC5D/CD3 | I/II | [8] |
Bachier CR | NCT05535244 | Cevostamab | IgG1 | 1 + 1 symmetric | FcRH5/CD3 | I/II | [11] |
Table 2
Outcomes of clinical trials of single-agent bispecific antibodies or combination therapy
NCT No. | N/A | NCT4649359 | NCT03761108 | NCT4984434 | NCT03399799 | NCT04586426 | NCT04108195 |
|---|---|---|---|---|---|---|---|
NCT04634552 | |||||||
Target | BCMA/CD3 | BCMA/CD3 | BCMA/CD3 | BCMA/CD3 | GPRC5D/CD3*** | BCMA/CD3 + GPRC5D/CD3 | GPRC5D/CD3 + CD38 |
Drug | Teclistamab | Elranatamab | Linvoseltamab | F182112 | Talquetamab | Teclistamab + Talquetamab | Talquetamab + Daratumumab |
Patient Number | 24 | 123 | 179 (200 mg: n = 75 50 mg: n = 104) | 16 | 143(QW) 145(Q2W) 51(prior T therapy) | 63 | 65 |
Median age (year) | 66 (51–80) | 68 (36–89) | 66** (37–90) | 64 (52–74) | N/A | 67 (39–81) | 63 (37–81) |
Median prior LOT | 7 (4–13) | 5 (2–22) | 5** (1–16) | ≥ 4 (56%) | 5–6 | 5 (1–11) | 5 (2–16) |
TCR MM | 100% | 96.7% | 81%** | N/A | 74% 69% 84% | 78% | 58% |
Median time to response(mo) | 0.53 | NR (95%CI, 12.9-NE) | N/A | N/A | N/A | N/A | 1 (0.9–8.3) |
ORR | 60% | 61%* (95%CI, 51.8–69.6) | 64%(include 12 patients in Phase I) 50% | 43.8% (95%CI, 19.8–70.1) | 74% 73% 63% | 84% | 78% |
≥CR | N/A | 31.7% | N/A | N/A | (≥ VGPR)59% 57% 53% | 34% | 45% |
Median follow-up(mo) | 1.3 | 12.8 (0.2–22.7) | 2.3 4.7 | 3.1 (0.9–11.7) | 14.9 8.6 11.8 | 14.4 (0.5–21.9) | 11.5 (1.0-27.3) |
Median PFS(mo) | N/A | NR | N/A | N/A | 7.5 11.9 5.1 | N/A | 19.4 |
Mediann OS(mo) | N/A | NR | N/A | N/A | N/A | N/A | N/A |
12-mo PFS | N/A | 57.1% (95%CI, 47.2%-65.9%) | N/A | N/A | N/A | N/A | 76% |
12-mo OS | N/A | 62% (95%CI, 52.8%-70%) | N/A | N/A | N/A | N/A | 93% |
CRS/ICANs | Gr 1–2 CRS 41% | N/A | Gr1-2 CRS:36% 51% Gr ≥ 3 ICANS:2% 1% | Gr 1–2 CRS: 81% | Gr1-2 CRS:79% ICANS:11% 75% 11% 77% 3% | Gr 1–2 CRS 78%; Gr 3 CRS 3%; ICANS :1patient | Gr 1–2 CRS 78%; Gr 1–2 ICANS 5% |
Infection | N/A | N/A | Gr1-2:17%;Gr ≥ 3:26% 28% 31% | N/A | 58% 65% 71% | N/A | 63% |
References | [4] | [5] | [6] | [7] | [8] | [9] | [10] |
Anzeige
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.